Table 2.
Unadjusted and adjusted logistic regression models showing the association with receipt of brachytherapy among patients with stage I–II breast cancer in 2005–2006*
| UNADJUSTED | ADJUSTED | |||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Odds Ratio | 95% CI | P-value | Odds Ratio | 95% CI | P-value | |||
| Patient characteristics | ||||||||
| Age group | .07 | |||||||
| 67–69 | 1.00 | – | – | |||||
| 70–74 | 0.88 | 0.42 | 1.83 | |||||
| 75–79 | 1.55 | 0.75 | 3.20 | |||||
| 80–89 | 0.60 | 0.27 | 1.30 | |||||
| Race | .28 | |||||||
| White | 1.00 | – | – | |||||
| Black | 0.15 | 0.02 | 1.53 | |||||
| Other | 1.08 | 0.27 | 4.33 | |||||
| Marital status | .35 | |||||||
| Married | 1.00 | – | – | |||||
| Unmarried | 0.69 | 0.41 | 1.15 | |||||
| Unknown | 1.04 | 0.31 | 3.45 | |||||
| Income | .92 | |||||||
| <$33K | 1.00 | – | – | |||||
| $33 – <$40K | 1.02 | 0.36 | 2.91 | |||||
| $40K – <$50K | 1.12 | 0.43 | 2.93 | |||||
| $50K – <$63K | 0.99 | 0.36 | 2.72 | |||||
| ≥$63K | 1.35 | 0.52 | 3.53 | |||||
| Clinical characteristics | ||||||||
| Stage | <.001 | <.001 | ||||||
| I | 1.00 | – | – | 1.00 | – | – | ||
| II | 0.17 | 0.08 | 0.39 | 0.17 | 0.08 | 0.39 | ||
| Laterality | .81 | |||||||
| Right | 1.00 | – | – | |||||
| Left | 0.94 | 0.58 | 1.53 | |||||
| Hormone status | .54 | |||||||
| Negative | 1.00 | – | – | |||||
| Positive | 1.06 | 0.48 | 2.36 | |||||
| Unknown | 1.88 | 0.54 | 6.53 | |||||
| Comorbid conditions | .29 | |||||||
| 0 | 1.00 | – | – | |||||
| 1–2 | 1.03 | 0.61 | 1.73 | |||||
| ≥3 | 0.52 | 0.22 | 1.24 | |||||
| Hospital characteristics | ||||||||
| Hospital brachytherapy use† | .47 | |||||||
| No | 1.00 | – | – | |||||
| Yes | 1.80 | 0.70 | 4.61 | |||||
| Unknown | 1.15 | 0.49 | 2.72 | |||||
| Teaching hospital | .32 | |||||||
| No | 1.00 | – | – | |||||
| Yes | 0.54 | 0.25 | 1.20 | |||||
| Unknown | 0.73 | 0.29 | 1.83 | |||||
| Total hospital beds | .03 | .02 | ||||||
| Q1 (<216) | 1.00 | – | – | 1.00 | – | – | ||
| Q2 (216 – 334) | 1.56 | 0.52 | 4.68 | 1.61 | 0.52 | 5.03 | ||
| Q3 (335 – 442) | 3.48 | 1.23 | 9.88 | 3.74 | 1.27 | 11.02 | ||
| Q4 (443 – 1161) | 0.65 | 0.19 | 2.18 | 0.61 | 0.17 | 2.19 | ||
| Unknown | 1.50 | 0.50 | 4.49 | 1.46 | 0.47 | 4.53 | ||
| Regional characteristics | ||||||||
| HRR-level two-year mammography rate | .73 | |||||||
| Q1 (52.4–58.1) | 1.00 | – | – | |||||
| Q2 (58.5–62.2) | 0.64 | 0.22 | 1.91 | |||||
| Q3 (62.2–65.4) | 1.16 | 0.43 | 3.13 | |||||
| Q4 (65.6–74.8) | 1.13 | 0.39 | 3.28 | |||||
| Surgeon characteristics | ||||||||
| Had an early-adopting peer in 2003–2004 | .04 | .03 | ||||||
| No | 1.00 | – | – | 1.00 | – | – | ||
| Yes | 3.19 | 1.05 | 9.70 | 3.40 | 1.11 | 10.38 | ||
*
N=2,087 patients assigned to 328 surgeons; analyses adjusted for clustering by surgeon
ˆ
Additional surgeon characteristics—patient volume in 2005–2006, number of peers in 2003–2004, and number of peers’ BCS patients in 2004–2004—were tested in unadjusted analyses and found not to be significantly associated with the receipt of brachytherapy. They were not included in the table for the sake of brevity.
†
Defined as whether the hospital had at least one assigned patient who underwent brachytherapy in 2003–2004
HRR: Hospital referral region